CAH

From a fundamental perspective, Cardinal Health's financials present a mixed picture. The company boasts a strong gross margin of 367.0% and an operating margin of 102.2%, indicating effective cost management. However, the EPS growth quarter-over-quarter has declined sharply by 19.5%, raising concerns about short-term profitability. Revenue growth has shown a robust 11.0% increase QoQ, but the year-over-year figure presents a stark decline of 187.3%, signaling potential challenges in sustaining revenue streams. The stock has a price-to-earnings (P/E) ratio of 33.9, which is relatively high compared to its forward P/E of 18.7, suggesting that the stock may be overvalued based on its growth trajectory. Analysts are generally positive, with a consensus rating of "BUY" and a target price of $245.27, indicating a potential upside of approximately 10% from current levels.

Looking ahead, Cardinal Health does not have an earnings release scheduled within the next 30 days, which may limit immediate catalysts for price movement. The last earnings report on March 31, 2026, highlighted the significant revenue drop, a factor to monitor closely as it could impact investor sentiment and valuation. One notable aspect to watch is the company’s ability to reverse the trend of declining EPS growth, as this will be crucial for maintaining investor confidence and achieving the analysts’ target price. Overall, the interplay between revenue recovery and margin sustainability will be pivotal in shaping Cardinal Health's market performance in the coming months.